Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Achieving evidence for the management of arthralgia at risk for RA. Response to: 'The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis' by Rothschild.

van der Helm-van Mil A, Landewé RB.

Ann Rheum Dis. 2020 Jan 24. pii: annrheumdis-2020-216984. doi: 10.1136/annrheumdis-2020-216984. [Epub ahead of print] No abstract available.

PMID:
31980548
2.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D.

Ann Rheum Dis. 2020 Jan 22. pii: annrheumdis-2019-216655. doi: 10.1136/annrheumdis-2019-216655. [Epub ahead of print]

3.

The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA.

van der Helm-van Mil A, Landewé RBM.

Ann Rheum Dis. 2020 Mar;79(3):312-315. doi: 10.1136/annrheumdis-2019-216716. Epub 2020 Jan 8. Review.

4.

Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.

Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM.

RMD Open. 2019 Nov 28;5(2):e001050. doi: 10.1136/rmdopen-2019-001050. eCollection 2019.

5.

Do we need new trial designs in spondyloarthritis?

Landewé RBM.

Semin Arthritis Rheum. 2019 Dec;49(3S):S8-S10. doi: 10.1016/j.semarthrit.2019.09.016.

PMID:
31779854
6.

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis.

Kiltz U, Landewé RBM, van der Heijde D, Rudwaleit M, Weisman MH, Akkoc N, Boonen A, Brandt J, Carron P, Dougados M, Gossec L, Jongkees M, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compán V, Niederman K, Sampaio-Barros PD, Slobodin G, Van den Bosch FE, van Tubergen A, van Weely S, Wiek D, Braun J.

Ann Rheum Dis. 2020 Feb;79(2):193-201. doi: 10.1136/annrheumdis-2019-216034. Epub 2019 Oct 11.

7.

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.

van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L.

Rheumatology (Oxford). 2019 Oct 5. pii: kez420. doi: 10.1093/rheumatology/kez420. [Epub ahead of print]

PMID:
31586420
8.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
9.

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.

Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O.

Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Epub 2019 Aug 14.

PMID:
31413005
10.

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaeybroeck B, Klaasen R, van Onna M, Bernelot Moens HJ, Visser H, Schilder AM, Kok MR, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

BMC Rheumatol. 2019 Jun 13;3:3. doi: 10.1186/s41927-019-0071-x. eCollection 2019. Erratum in: BMC Rheumatol. 2019 Aug 20;3:35.

11.

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, Setiadi AF, Kelly S, Bene F, DiCicco M, Riahi S, Rocher V, Ng N, Lazarou I, Hands R, van der Heijde D, Landewé RBM, van der Helm-van Mil A, Cauli A, McInnes I, Buckley CD, Choy EH, Taylor PC, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.

12.

Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.

Boone NW, Sepriano A, van der Kuy PH, Janknegt R, Peeters R, Landewé RBM.

RMD Open. 2019 Jan 22;5(1):e000836. doi: 10.1136/rmdopen-2018-000836. eCollection 2019.

13.

Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA).

Putrik P, Ramiro S, Moltó A, Keszei AP, Norton S, Dougados M, van der Heijde D, Landewé RBM, Boonen A.

Ann Rheum Dis. 2019 Apr;78(4):486-493. doi: 10.1136/annrheumdis-2018-214259. Epub 2019 Jan 23.

PMID:
30674477
14.

Response to: 'Catching the falling star: points to consider when using propensity scores' by Ouyang et al.

Bergstra SA, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2020 Mar;79(3):e27. doi: 10.1136/annrheumdis-2018-214892. Epub 2018 Dec 30. No abstract available.

PMID:
30598466
15.

Response to: 'Metering the METEOR in methotrexate failure: is propensity score a falling star?' by Ahmed et al.

Bergstra SA, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2019 Dec;78(12):e132. doi: 10.1136/annrheumdis-2018-214652. Epub 2018 Nov 14. No abstract available.

PMID:
30429121
16.

How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies.

Bergstra SA, Winchow LL, Murphy E, Chopra A, Salomon-Escoto K, Fonseca JE, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2019 Jan;78(1):25-30. doi: 10.1136/annrheumdis-2018-213731. Epub 2018 Oct 16.

PMID:
30327328
17.

Are gender-specific approaches needed in diagnosing early axial spondyloarthritis? Data from the SPondyloArthritis Caught Early cohort.

Ortolan A, van Lunteren M, Ramiro S, Ramonda R, Landewé RBM, Dagfinrud H, Jacobsson LTH, van der Heijde D, van Gaalen FA.

Arthritis Res Ther. 2018 Oct 1;20(1):218. doi: 10.1186/s13075-018-1705-x.

18.

Validation and reliability of translation of the ASAS Health Index in a Colombian Spanish-speaking population with spondyloarthritis.

Bautista-Molano W, Landewé RBM, Kiltz U, Valle-Oñate R, van der Heijde D.

Clin Rheumatol. 2018 Nov;37(11):3063-3068. doi: 10.1007/s10067-018-4308-7. Epub 2018 Sep 26.

PMID:
30259248
19.

Response to: 'Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis' by Ferreira et al.

Landewé RBM.

Ann Rheum Dis. 2019 Oct;78(10):e110. doi: 10.1136/annrheumdis-2018-214221. Epub 2018 Aug 20. No abstract available.

PMID:
30127057
20.

Response to: 'Early identification of rheumatoid arthritis; the risk of overtreatment in perspective' by Landewé.

Landewé RBM.

Ann Rheum Dis. 2019 Oct;78(10):e108. doi: 10.1136/annrheumdis-2018-214172. Epub 2018 Aug 10. No abstract available.

PMID:
30097455
21.

Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.

Bergstra SA, Branco JC, Vega-Morales D, Salomon-Escoto K, Govind N, Allaart CF, Landewé RBM.

Ann Rheum Dis. 2018 Oct;77(10):1413-1420. doi: 10.1136/annrheumdis-2018-213289. Epub 2018 Jul 6.

PMID:
29980576
22.

Overdiagnosis and overtreatment in rheumatology: a little caution is in order.

Landewé RBM.

Ann Rheum Dis. 2018 Oct;77(10):1394-1396. doi: 10.1136/annrheumdis-2018-213700. Epub 2018 Jul 4.

PMID:
29973350
23.

Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.

Bergstra SA, Allaart CF, Ramiro S, Chopra A, Govind N, Silva C, Murphy EA, Landewé RBM.

J Rheumatol. 2018 Oct;45(10):1361-1366. doi: 10.3899/jrheum.171176. Epub 2018 Jun 15.

PMID:
29907672
24.

Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study.

Rodrigues Manica S, Sepriano A, Ramiro S, Pimentel Santos F, Putrik P, Nikiphorou E, Norton S, Molto A, Dougados M, van der Heijde D, Landewé RBM, van den Bosch FE, Boonen A.

Ann Rheum Dis. 2018 Sep;77(9):1303-1310. doi: 10.1136/annrheumdis-2018-213464. Epub 2018 Jun 2.

PMID:
29860232
25.

"Big Data" in Rheumatology: Intelligent Data Modeling Improves the Quality of Imaging Data.

Landewé RBM, van der Heijde D.

Rheum Dis Clin North Am. 2018 May;44(2):307-315. doi: 10.1016/j.rdc.2018.01.007. Review.

PMID:
29622297
26.

Are MRI-detected erosions specific for RA? A large explorative cross-sectional study.

Boeters DM, Nieuwenhuis WP, van Steenbergen HW, Reijnierse M, Landewé RBM, van der Helm-van Mil AHM.

Ann Rheum Dis. 2018 Jun;77(6):861-868. doi: 10.1136/annrheumdis-2017-212252. Epub 2018 Feb 28.

27.

The nocebo effect challenges the non-medical infliximab switch in practice.

Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, Janknegt R, Peeters R, Landewé RBM, Winkens B, van Bodegraven AA.

Eur J Clin Pharmacol. 2018 May;74(5):655-661. doi: 10.1007/s00228-018-2418-4. Epub 2018 Jan 24.

28.

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.

van der Heijde D, Baraliakos X, Hermann KA, Landewé RBM, Machado PM, Maksymowych WP, Davies OR, de Peyrecave N, Hoepken B, Bauer L, Nurminen T, Braun J.

Ann Rheum Dis. 2018 May;77(5):699-705. doi: 10.1136/annrheumdis-2017-212377. Epub 2018 Jan 17.

29.

Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.

Nikiphorou E, van der Heijde D, Norton S, Landewé RB, Molto A, Dougados M, Van den Bosch FE, Ramiro S.

Ann Rheum Dis. 2018 Mar;77(3):405-411. doi: 10.1136/annrheumdis-2017-212457. Epub 2017 Dec 8.

PMID:
29222349
30.

Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.

Bergstra SA, Allaart CF, van den Berg R, Chopra A, Govind N, Huizinga TWJ, Landewe RBM.

Arthritis Res Ther. 2017 Nov 22;19(1):258. doi: 10.1186/s13075-017-1468-9.

31.

An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS.

Molto A, Gossec L, Meghnathi B, Landewé RBM, van der Heijde D, Atagunduz P, Elzorkany BK, Akkoc N, Kiltz U, Gu J, Wei JCC, Dougados M; ASAS-FLARE study group.

Ann Rheum Dis. 2018 Jan;77(1):124-127. doi: 10.1136/annrheumdis-2017-212178. Epub 2017 Oct 16.

PMID:
29038299
32.

Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis.

Dougados M, Maksymowych WP, Landewé RBM, Moltó A, Claudepierre P, de Hooge M, Lambert RG, Bonin R, Bukowski JF, Jones HE, Logeart I, Pedersen R, Szumski A, Vlahos B, van der Heijde D.

Ann Rheum Dis. 2018 Feb;77(2):221-227. doi: 10.1136/annrheumdis-2017-212008. Epub 2017 Sep 29.

33.

Validation of the EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.

Burgers LE, Siljehult F, Ten Brinck RM, van Steenbergen HW, Landewé RBM, Rantapää-Dahlqvist S, van der Helm-van Mil AHM.

Rheumatology (Oxford). 2017 Dec 1;56(12):2123-2128. doi: 10.1093/rheumatology/kex324.

PMID:
28968699
34.

Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.

Bergstra SA, Olivas O, Akdemir G, Riyazi N, Collée G, van Groenendael JHLM, Landewé RBM, Allaart CF.

Arthritis Res Ther. 2017 Sep 30;19(1):220. doi: 10.1186/s13075-017-1425-7.

35.

Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.

Bergstra SA, Landewé RBM, Huizinga TWJ, Allaart CF.

Rheumatology (Oxford). 2017 Oct 1;56(10):1721-1728. doi: 10.1093/rheumatology/kex236.

PMID:
28957556
36.

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.

Molnar C, Scherer A, Baraliakos X, de Hooge M, Micheroli R, Exer P, Kissling RO, Tamborrini G, Wildi LM, Nissen MJ, Zufferey P, Bernhard J, Weber U, Landewé RBM, van der Heijde D, Ciurea A; Rheumatologists of the Swiss Clinical Quality Management Program.

Ann Rheum Dis. 2018 Jan;77(1):63-69. doi: 10.1136/annrheumdis-2017-211544. Epub 2017 Sep 22.

37.

Alternative diagnoses in patients with chronic back pain not diagnosed with axial spondyloarthritis: data from the SPACE cohort.

Ez-Zaitouni Z, Landewé RBM, van der Heijde D, van Gaalen FA.

Ann Rheum Dis. 2018 Jun;77(6):e34. doi: 10.1136/annrheumdis-2017-212175. Epub 2017 Aug 22. No abstract available.

PMID:
28830880
38.

Response to: 'The GRAPPA-OMERACT initiative to standardise outcomes in Psoriatic Arthritis clinical trials and longitudinal observational studies' by Tillet et al.

Ramiro S, Smolen JS, Landewé RBM, van der Heijde D, Gossec L.

Ann Rheum Dis. 2018 May;77(5):e24. doi: 10.1136/annrheumdis-2017-212012. Epub 2017 Aug 16. No abstract available.

PMID:
28814427
39.

Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.

Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, Tchetverikov I, Vreugdenhil SA, van Woerkom JM, Goekoop-Ruiterman YPM, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):516-524. doi: 10.1002/acr.23315.

40.

The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts.

Ez-Zaitouni Z, Bakker PA, van Lunteren M, de Hooge M, van den Berg R, Reijnierse M, Fagerli KM, Landewé RB, Ramonda R, Jacobsson LT, Saraux A, Lenczner G, Feydy A, Pialat JB, Thévenin F, van Gaalen FA, van der Heijde D.

Ann Rheum Dis. 2017 Oct;76(10):1731-1736. doi: 10.1136/annrheumdis-2017-211486. Epub 2017 Jun 29.

PMID:
28663306
41.

Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra et al.

Smolen JS, Landewé RBM, van der Heijde D.

Ann Rheum Dis. 2017 Nov;76(11):e48. doi: 10.1136/annrheumdis-2017-211455. Epub 2017 May 6. No abstract available.

PMID:
28478402
42.

Response to: 'The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Pirilä et al.

Smolen JS, Landewé RBM, van der Heijde D.

Ann Rheum Dis. 2017 Dec;76(12):e50. doi: 10.1136/annrheumdis-2017-211524. Epub 2017 Apr 27. No abstract available.

PMID:
28450310
43.

The influence of discrepant imaging judgements on the classification of axial spondyloarthritis is limited: a replication in the SpondyloArthritis Caught Early (SPACE) cohort.

Ez-Zaitouni Z, van Lunteren M, Bakker PAC, van den Berg R, Reijnierse M, Fagerli KM, Landewé RBM, Ramonda R, Jacobsson LTH, van Gaalen FA, van der Heijde D.

Ann Rheum Dis. 2018 Jan;77(1):e1. doi: 10.1136/annrheumdis-2017-211553. Epub 2017 Apr 17. No abstract available.

PMID:
28416518
44.

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?

Bouman CA, den Broeder AA, van der Maas A, van den Hoogen FH, Landewé RB, van Herwaarden N.

RMD Open. 2017 Mar 20;3(1):e000327. doi: 10.1136/rmdopen-2016-000327. eCollection 2017.

45.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RBM.

Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi: 10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15. Review.

PMID:
28298374
46.

Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.

Bergstra SA, Allaart CF, Stijnen T, Landewé RBM.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1473-1483. doi: 10.1002/acr.23164. Epub 2017 Aug 31. Review.

47.

Why CAPS criteria are not diagnostic criteria?

Landewé RB, van der Heijde DM.

Ann Rheum Dis. 2017 Apr;76(4):e7. doi: 10.1136/annrheumdis-2016-210656. Epub 2016 Oct 31. No abstract available.

PMID:
27799158
48.
49.

Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives.

Bergstra SA, Machado PM, van den Berg R, Landewé RB, Huizinga TW.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S87-S90. Epub 2016 Oct 19. Review.

50.

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials.

Landewé RB, Connell CA, Bradley JD, Wilkinson B, Gruben D, Strengholt S, van der Heijde D.

Arthritis Res Ther. 2016 Sep 23;18(1):212.

Supplemental Content

Loading ...
Support Center